Increased cytotoxicity and bystander effect of 5-fluorouracil and 5'-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase

British Journal of Cancer

Volumn 80, Issue 11, 1999, Pages 1726-1733

  Evrard, A ^a   Cuq, P ^a   Ciccolini, J ^b   Vian, L ^a   Cano, J P ^a  

^a UNIV MONTPELLIER   (France)

^b Lab de Toxicocinetique et P   (France)

Author keywords

5' DFUR; 5 FU; Bystander effect; Cancer gene therapy; Thymidine phosphorylase

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DOXIFLURIDINE; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; TRITIUM;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; DNA TRANSFECTION; DRUG CYTOTOXICITY; DRUG METABOLISM; DRUG SENSITIVITY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; CLONING, MOLECULAR; COLORECTAL NEOPLASMS; DNA, COMPLEMENTARY; FLOXURIDINE; FLUOROURACIL; HUMANS; RECOMBINANT PROTEINS; THYMIDINE PHOSPHORYLASE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032797555     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690589     Document Type: Article

References (47)

1. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254
2. Chen CY, Chang YN, Ryan P. Linscott M, McGarrity GJ and Chiang YL (1995) Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the 'bystander effect'. Hum Gene Ther 6: 1467-1476
3. Chen L and Waxman DJ (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazophosphorines following cytochrome P-450 gene transfer development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res 55: 581-589
4. Chu E, Lai GM, Zinn S and Allegra CJ (1990) Resistance of a human ovarian cancer line to 5-fluorouracil associated with decreased levels of 5-fluorouracil in DNA. Mol Pharmacol 38: 410-417
5. Cohen AM, Minsky BD and Schilsky RL (1993) Colon cancer. In: Cancer, Principles and Practices of Oncology. 4th edn. Devita VT, Hellman S and Rosenberg SA (eds). pp. 929-977. JB Lippincott: Philadelphia
6. Denning C and Pitts JD (1997) Bystander effect of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther 8: 1825-1835
7. Desgranges C, Razaka G and Rabaud H (1981) Catabolism of thymidine in human blood platelets - purification and properties of thymidine phosphorylase. Biochim Biophys Acta 654: 211-218
8. Elias L and Crismann HA (1988) Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites Cancer Res 48: 4868-4873
9. Evrard A, Vian L, Aubert C and Cano JP (1996) An in vitro nucleoside analog screening method for cancer gene therapy. Cell Biol Toxicol 12: 345-350
10. Evrard A, Cuq P, Robert B, Vian L, Pèlegrin A and Cano JP (1999) Enhancement of 5-fluorouracil cytotoxicity by human thymidine phosphorylase expression in cancer cells: in vitro and in vivo study. Int J Cancer 80: 465-470
11. Fick J, Barker FG II, Dazin P, Westphale EM, Beyer EC and Israel MA (1995) The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA 92: 11071-11075
12. Fox SB, Moghaddam A, Westwood M, Turley H, Bicknell R, Gatter KC and Harris AL (1995) Platelet-derived endothelial cell growth factor thymdine phosphorylase expression in normal tissues - an immunohistochemical study. J Pathol 176: 183-190
13. Fox SB, Engels K, Comley M, Whitehouse RM, Turley H, Gatter KC and Harris AL (1997) Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann Oncol 8: 271-275
14. Freeman SM, Abhoud CM, Whartenby KA, Packmann CH, Koeplin DS, Moolten FL and Abraham GN (1993) The 'bystander effect': tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 53: 5274-5283
15. Friedkin M and Roberts D (1953) The enzymatic synthesis of nucleosides. Thymidine phosphorylase in mammalian tissue. J Biol Chem 207: 245-256
16. Grem JL and Fischer PH (1986) Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole wilh a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6191-6199
17. Griffiths L and Stratford IJ (1997) Platelet derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76: 689-693
18. Haraguchi M, Furukawa T, Sumizawa T and Akiyama S (1993) Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 53: 5680-5682
19. Huber BE, Austin EA, Good SS, Knick VC, Tibells S and Richard CA (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 53: 4619-4626
20. Huber BE, Austin EA, Richards CA, Davis ST and Good SS (1994) Metabolism of 5-fluorocytosine in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306
21. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A and Maruyama HB (1980) Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluornuridine. Jpn J Cancer Res 71: 112-123
22. Kato Y, Matsukawa S, Muraoka R and Tanigawa N (1997) Enhancement of drug sensitivity and a bystander effect in PC 9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br J Cancer 75: 506-511
23. Krenitsky TA (1968) Pentosyl transfer machanisms of the mammalian nucleoside phosphorylase. J Biol Chem 243: 2871-2875
24. Lonn U, Lonn S, Nylen U and Winblad G (1989) 5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole. Cancer Res 49: 1085-1089
25. Luccioni C, Beaumatin J, Bardot V and Lefrancois D (1994) Pyrimidine nucleotide metabolism in human colon carcinomas: comparison of normal tissues, primary tumors and xenografts. Int J Cancer 58: 517-522
26. Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, Jakesz R, Rainer H and Steger GG (1997) Transcription and activity of 5-fluorouracil convening enzymes in fluoropyrimidines resistance in colon cancer in vitro. Biochem Pharmacol 54: 1233-1242
27. Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y and Akiyama S (1995) Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res 55: 1687-1690
28. Miyazono K, Okabe T, Urabe A, Takaku F and Heldin CH (1987) Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 262: 4098-4103
29. Moghaddam A and Bicknell R (1992) Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry 31: 12141-12146
30. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46: 5276-5281
31. Moolten FL and Wells JM (1990) Curability of tumors hearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 82: 297-300
32. Müllen CA, Kilstrup M and Blaese RM (1992) Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37
33. Nishida M, Hino A, Mori K, Matsumoto T, Yoshikubo T and Ishitsuka H (1996) Preparation of anti-human thymidine phosphorylase monoclonal antibodies useful for detecting the enzyme levels in tumor tissues. Biol Pharm Bull 19: 1407-1411
34. O'Brien TS, Fox SB, Dickinson AJ, Turley H, Westwood M, Moghaddam A, Gatter KC, Bicknell R and Harris AL (1996) Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. Cancer Res 56: 4799-4804
35. Parker WB, King SA, Allan PW, Lee Bennett Jr L, Seerist JA III, Montgomey JA, Gilbert KS, Waud WR, Wells AH, Gillespie GY and Sorscher EJ (1997) In vivo gene therapy with E. coli purine nucleoside phosphorylase. Hum Gene ther 8: 1637-1644
36. Patterson AV, Zhang H, Moghaddam A, Bicknell R, Talbot DC, Straford IJ and Harris AL (1995) Increased sensitivity to the prodrug 5′ deoxy-5-fluorouridine and modulation of 5-fluoro-2′-desoxyuridine sensitivity in MCF 7 cells transfected with thymidine phosphorylase. Br J Cancer 72: 669-675
37. Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H and Seeber S (1997) Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 15: 389-400
38. Schwartz EL, Baptiste N, O'Connor CJ, Wadler S and Otter BA (1994) Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase. Cancer Res 54: 1472-1478
39. Schwartz EL, Baptiste N, Wadler S and Makower D (1995) Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J Biol Chem 270: 19073-19077
40. Schwartz EL, Wan E, Wang FS and Baptiste N (1998) Regulation of expression of thymidine phosphorylase/platelet derived endothelial cell growth factor in human colon carcinoma cells. Cancer Res 58: 1551-1557
41. Shaw J, Smillie RH, Miller AE and MacPhee DG (1988) The role of blood platelets in nucleoside metabolism: regulation of thymidine phosphorylase. Mutat Res 200: 117-131
42. Sobrero AF, Aschele C and Bertino JR (1997) Fluorouracil in colorectal cancer. A tale of two drugs: implications for biochemical modulation. J Clin Oncol 15: 368-381
43. Sumizawa T, Furukawa T, Haraguchi M, Yoshimura A, Takeyasu A, Ishizawa M, Yamada Y and Akiyama S (1993) Thymidine phosphorylase activity associated with platelet-derived endothelial cell growth factor. J Biochem 114: 9-14
44. Trinh QT, Austin EA, Murray DM, Knick VC and Huber BE (1995) Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 55: 4808-4812
45. Wei MX, Tamiya T, Chase M, Boviatsis EJ, Chang TKH, Kowall NW, Hochberg FH, Waxman DJ, Breakefield XO and Chiocca EA (1994) Experimental tumor therapy in mice using the cyclophosphamide activating cytochrome P450 2B1 gene. Hum Gene Ther 5: 969-978
46. Yoshimura A, Kuwazuru Y, Furukawa T, Yoshida H, Yamada K and Akiyama S (1900) Purification and tissue distribution of human thymidine phosphorylase: high expression in lymphocytes, reticulocytes and tumors. Biochim Biophys Acta 1034: 107-113
47. Zimmerman M and Seidenberg J (1964) Deoxyribosyl transfer. Thymidine phosphorylase and nucleoside deoxyribosyltransferase in normal and malignant tissue. J Biol Chem 230: 2618-2621